Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Complement activation in patients with neuromyelitis optica
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4408172
Author(s) Nytrova, Petra; Potlukova, Eliska; Kemlink, David; Woodhall, Mark; Horakova, Dana; Waters, Patrick; Havrdova, Eva; Zivorova, Dana; Vincent, Angela; Trendelenburg, Marten
Author(s) at UniBasel Trendelenburg, Marten
Year 2014
Title Complement activation in patients with neuromyelitis optica
Journal Journal of Neuroimmunology
Volume 274
Number 1-2
Pages / Article-Number 185-91
Keywords Adolescent; Adult; Aged; Aquaporin 4/immunology; Autoantibodies/blood/immunology; Complement Activation/*immunology; Complement C1q/*immunology/metabolism; Complement C3a/*immunology/metabolism; Female; Follow-Up Studies; Humans; Immunoglobulin G/blood/immunology; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting/*immunology; Neuromyelitis Optica/*immunology; Prospective Studies; Young Adult; Aquaporin-4 IgG; C1q antibodies; Complement; Neuromyelitis optica
Mesh terms Adolescent; Adult; Aged; Aquaporin 4, immunology; Autoantibodies, immunology; Complement Activation, immunology; Complement C1q, metabolism; Complement C3a, metabolism; Female; Follow-Up Studies; Humans; Immunoglobulin G, immunology; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting, immunology; Neuromyelitis Optica, immunology; Prospective Studies; Young Adult
Abstract The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition.
Publisher Elsevier
ISSN/ISBN 0165-5728 ; 1872-8421
URL https://www.ncbi.nlm.nih.gov/pubmed/25109258
edoc-URL https://edoc.unibas.ch/62495/
Full Text on edoc No
Digital Object Identifier DOI 10.1016/j.jneuroim.2014.07.001
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/25109258
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.360 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
30/04/2024